MicroRNA‑98‑5p regulates the proliferation and apoptosis of A549 cells by targeting MAP4K3

Wang,Ziquan; Han,Zhengxiang; Zhang,Lansheng; Zhang,Shiqiang; Wang,Baoqing

doi:10.3892/ol.2019.10771

MicroRNA‑98‑5p regulates the proliferation and apoptosis of A549 cells by targeting MAP4K3

Authors:
- Ziquan Wang
- Zhengxiang Han
- Lansheng Zhang
- Shiqiang Zhang
- Baoqing Wang
View Affiliations

Affiliations: Department of Medical Oncology, General Hospital of Xuzhou Mining Group, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221006, P.R. China, Department of Medical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, P.R. China
Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10771
Pages: 4288-4293

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is a primary subtype of lung cancer that is accompanied by a high incidence rate and poor prognosis. The primary treatment for NSCLC is chemotherapy, which has low effectiveness and high toxicity. Thus, novel targeted therapy has drawn much attention in recent years. MicroRNAs (miRs) serve important roles in multiple cancer types. In the current study, a decrease in miR‑98‑5p and an increase in mitogen‑activated protein kinase kinase kinase kinase 3 (MAP4K3) was observed in NSCLC tumor tissues compared with normal tissues. miR‑98‑5p was predicted to target positions 1,056‑1,063 of the MAP4K3 3'‑untranslated region (UTR). The binding sites between miR‑98‑5p and the 3'‑UTR of MAP4K3 messenger RNA were supported by the results of a dual‑luciferase reporter assay. Compared with the control and miR‑negative control (NC) groups, miR‑98‑5p mimic significantly reduced cell proliferation and increased apoptosis in NSCLC cells. In addition, miR‑98‑5p mimic reduced the expression of MAP4K3 and mammalian target of rapamycin while increasing the expression of cleaved caspase‑3 compared with the control group and miR‑NC groups. In conclusion, miR‑98‑5p may inhibit the progression of NSCLC via targeting of MAP4K3.

View Figures

View References

1	Dent AG, Sutedja TG and Zimmerman PV: Exhaled breath analysis for lung cancer. J Thorac Dis. 5:S540–S550. 2013.PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	World Health Organization Classification of Tumors, . Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and HeartWilliam D, Travis WD, Elisabeth Brambilla E, Konrad Müller-Hermelink H and Harris CC: IARC Press; Lyon: 2004
4	Wang T, Nelson RA, Bogardus A and Grannis FW Jr: Five-year lung cancer survival: Which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hu MC, Qiu WR, Wang X, Meyer CF and Tan TH: Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev. 10:2251–2264. 1996. View Article : Google Scholar : PubMed/NCBI
6	Diener K, Wang XS, Chen C, Meyer CF, Keesler G, Zukowski M, Tan TH and Yao Z: Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. Proc Natl Acad Sci USA. 94:9687–9692. 1997. View Article : Google Scholar : PubMed/NCBI
7	Chuang HC, Sheu WH, Lin YT, Tsai CY, Yang CY, Cheng YJ, Huang PY, Li JP, Chiu LL, Wang X, et al: HGK/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance. Nat Commun. 5:46022014. View Article : Google Scholar : PubMed/NCBI
8	Chen YR and Tan TH: Mammalian c-Jun N-terminal kinase pathway and STE20-related kinases. Gene Ther Mol Biol. 4:83–98. 1999.
9	Chen YR and Tan TH: The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol. 16:651–662. 2000.PubMed/NCBI
10	MacCorkle RA and Tan TH: Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys. 43:451–461. 2005. View Article : Google Scholar : PubMed/NCBI
11	Lam D, Dickens D, Reid EB, Loh SH, Moisoi N and Martins LM: MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins. Proc Natl Acad Sci USA. 106:11978–11983. 2009. View Article : Google Scholar : PubMed/NCBI
12	Liu L, Lu L, Zheng A, Xie J, Xue Q, Wang F, Wang X, Zhou H, Tong X, Li Y, et al: miR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma. Oncotarget. 8:13666–13677. 2017.PubMed/NCBI
13	Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, Zheng Q, Ma Y, Zhang J, Wu N and Yang Y: MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett. 342:43–51. 2014. View Article : Google Scholar : PubMed/NCBI
14	Hsu CP, Chuang HC, Lee MC, Tsou HH, Lee LW, Li JP and Tan TH: GLK/MAP4K3 overexpression associates with recurrence risk for non-small cell lung cancer. Oncotarget. 7:41748–41757. 2016. View Article : Google Scholar : PubMed/NCBI
15	Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
16	Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
17	Bueno MJ, Pérez de Castro I and Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle. 7:3143–3148. 2008. View Article : Google Scholar : PubMed/NCBI
18	Jovanovic M and Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X, Li Y and Wu S: miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 9:4472018. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using realtime quantitative PCR and the 2(Delta Delta C(T)) method. Methods. 25:4024082001. View Article : Google Scholar
21	Chuang JC, Neal JW, Niu XM and Wakelee HA: Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer. 90:172015. View Article : Google Scholar
22	NSCLC Metaanalyses Collaborative Group, ; Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable nonsmallcell lung cancer: Two metaanalyses of individual patient data. Lancet. 375:126712772010.
23	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
24	Dumache R, Rogobete AF, Andreescu N and Puiu M: Genetic and epigenetic biomarkers of molecular alterations in oral carcinogenesis. Clin Lab. 61:1373–1381. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zahran F, Ghalwash D, Shaker O, Al-Johani K and Scully C: Salivary microRNAs in oral cancer. Oral Dis. 21:739–747. 2015. View Article : Google Scholar : PubMed/NCBI
26	Soulard A and Hall MN: SnapShot: mTOR signaling. Cell. 129:4342007. View Article : Google Scholar : PubMed/NCBI